actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The properties of quantum dots can be also tuned by the synthetic scheme, high temperature solvent/ligand mixtures that influence the nanocrystal properties. High-quality QD contrast agents are obtained at elevated temperatures; however, because they have lower water solubility, their usage as cell markers is limited. Further functionalization with hydrophilic ligands is required. The advantages of QD are represented by their fast action; they are able to label a target tissue or cell in seconds. In vivo studies show that QD are able to selectively label cancer cells, and they accumulate at tumor sites. Tumor cells labeled with QD can be tracked with multiphoton microscopy as they invade lung tissue. In both studies, spectral imaging and autofluorescent subtraction allowed multicolour in vivo visualization of cells and tissues. A major drawback of QD is their relatively high toxicity. Functionalizations with different substrates that increase bioaffinity and decrease toxicity are in progress. For instance, sulfur from the QD shell is able to form reversible disulfide bonds with a wide class of organic compounds.
== Clinical significance == Clinically important research of gel based in vitro 3D model for the osteocytic potentiality of human CD34+ stem cells has been described. The results confirm that the human CD34+ stem cells possess unique osteogenic differentiation potential and can be used in the early regeneration of injured bone. Osteocytes die as a consequence of senescence, degeneration/necrosis, apoptosis (programmed cell death), and/or osteoclastic engulfment. The percentage of dead osteocytes in bone increases with age from less than 1% at birth to 75% after age 80. Osteocyte apoptosis is thought to be related to decreased mechanotransduction, which possibly leads to the development of osteoporosis. Apoptotic osteocytes release apoptotic bodies expressing RANKL to recruit osteoclasts. Mechanical loading increases osteocyte viability in vitro, and contributes to solute transport through the lacuno-canalicular system in bone, which enhances oxygen and nutrient exchange and diffusion to osteocytes. Skeletal unloading has been shown to induce osteocyte hypoxia in vivo, this is when osteocytes undergo apoptosis and recruit osteoclasts to resorb bone. Microdamage in bone occurs as the result of repetitive events of cycling loading, and appears to be associated with osteocyte death by apoptosis, which appear to secrete a signal to target osteoclasts to perform remodeling at a damaged site.
== Personal life == Townsend was born in Leytonstone, Greater London. He is the son of Troy Townsend, Head of Development for Kick It Out. He is of paternal Jamaican and maternal Greek Cypriot descent. He was brought up in Chingford, and is a lifelong Tottenham fan. He attended Rush Croft Sports College. When Townsend was 10, his half-brother Kurtis died in a car accident, aged 18. One of his cousins is Colin Kazim-Richards, also a professional footballer. Townsend was filmed singing the song "Stand By Me" by Ben E. King with the rest of the Tottenham youth players in the dressing room, which became a popular internet video. Townsend said in a December 2019 interview that he had been a problem gambler, compulsively betting online on football. He lost £46,000 on a single bet in 2012 on the night before a play-off game for Birmingham. After being caught for breaking the FA's anti-betting rules, he went to counselling. In November 2023, while on a short-term contract with Luton Town, Townsend said he was trying to improve his fitness and prolong his career. He highlighted his consumption of chicken feet, which are high in collagen as a boost to his overall fitness. Townsend worked as a pundit and co-commentator for ITV during the 2022 World Cup, Euro 2024 and 2026 World Cup. In May 2026, Townsend posted a social media video questioning why people needed to wear sunglasses to protect their eyes from sunlight but not from artificial light.
== See also == Biomaterials Bioplastic Biopolymers & Cell (journal) Condensation polymers Condensed tannins DNA sequence Food microbiology § Microbial biopolymers Melanin Non food crops Phosphoramidite Polymer chemistry Sequence-controlled polymers Sequencing Small molecules Worm-like chain
== Production == Unlike plutonium-238, plutonium-239, plutonium-240, plutonium-241, and plutonium-242, plutonium-244 is not produced in quantity by the nuclear fuel cycle, because further neutron capture on plutonium-242 produces plutonium-243 which has a short half-life (~5 hours) and quickly beta decays to americium-243 before having much opportunity to further capture neutrons in any but very high neutron flux environments. The global inventory of 244Pu is about 20 grams. Plutonium-244 is also a minor constituent of thermonuclear fallout, with a global 244Pu/239Pu fallout ratio of (5.7 ± 1.0) × 10−5.
Sources: en.wikipedia.org
However, the advent of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmacoeconomic concerns because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. This factor has been particularly relevant since many biological medications are used to treat chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of otherwise untreatable cancer during the remainder of life. The cost of treatment with a typical monoclonal antibody therapy for relatively common indications is generally in the range of €7,000–14,000 per patient per year. Older patients who receive biologic therapy for diseases such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis are at increased risk for life-threatening infection, adverse cardiovascular events, and malignancy. The first such substance approved for therapeutic use was biosynthetic "human" insulin made via recombinant DNA. Sometimes referred to as rHI, under the trade name Humulin, was developed by Genentech, but licensed to Eli Lilly and Company, who manufactured and marketed it starting in 1982. Major kinds of biopharmaceuticals include:
from the Miocene strata of the Santalla Formation (Spain), representing the first large vertebrate from the El Bierzo Basin reported to date. A study on deciduous teeth and juvenile skulls of members of the genus Chilotherium, providing evidence of utility of dental characters for species discrimination, is published by Kampouridis et al. (2026). Pandolfi, Codrea & Solomon (2026) describe fossil material of a member of the genus Acerorhinus from the Miocene strata from the Crețești 1 site (Romania), with greatest similarity to A. simplex, and refine the species content of the genus Acerorhinus. Titov et al. (2026) describe fossil material of Elasmotherium chaprovicum from the Pleistocene strata from the Taurida Cave (Crimea), including the first upper milk teeth of a member of the genus Elasmotherium reported to date. Ponomarev et al. (2026) report the discovery of fossil material of Stephanorhinus kirchbergensis in the Pleistocene strata from the Komi Republic (Russia), representing the northernmost record of the species in Europe reported to date. Uzunidis & Pandolfi (2026) report evidence of different dynamics of evolution of body mass of the narrow-nosed rhinoceros from Northern Europe and from the Mediterranean, as well as evidence of consistent mixed-feeding strategy in the studied species, with seasonal specialization toward either browsing or grazing in populations near the end of the temporal range of the species.
Diacetyl production is favored in fermentations that run warm with temperatures between 18 and 25 °C (64 and 77 °F). It also tends to be produced at higher levels in wines with lower pH levels (under 3.5), though at levels below 3.2, most strains of LAB desirable for MLF tend to be inhibited. "Wild" (as in uninoculated) malolactic ferments have the potential to produce more diacetyl than inoculated ferments due to the lower initial populations during the lag phase with inoculated ferments usually having an initial inoculum of 106 CFU/mL. Late MLF inoculations, after alcoholic fermentation, also tend to produce higher levels of diacetyl. Chardonnay producers desiring to make the high-diacetyl "buttery style" will often do late or "wild" inoculation in the barrel after primary fermentation, allowing the wine to spend several weeks or even months sur lie in reductive conditions that promote diacetyl production. Some sources point out that diacetyl is actually decreased by sur lie, due to surviving yeast metabolizing diacetyl, and therefore malolactic fermentation is best performed apart from lees. With wines that have excessive levels of diacetyl, some winemakers use sulfur dioxide to bind with the compound and reduce the perception of diacetyl by 30 to 60%. This binding is a reversible process and after only a few weeks aging in the bottle or tank, the high levels of diacetyl return.
Platelets also promote angiogenesis and tissue regeneration to maintain overall vascular integrity by releasing growth factors like vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Their multifunctional role displays the challenge of innovating synthetic platelets capable of effectively replicating their physiological functions.
== Early political career == In 2019, Kiggans ran for the Virginia Senate for the 7th district, which was being vacated by Republican incumbent Frank Wagner. In the Republican Party primary, Kiggans defeated Virginia Beach School Board member Carolyn Weems, 52% to 48%. In the general election, Kiggans faced Democratic state Delegate Cheryl Turpin. The race was viewed as competitive, as the district had very narrowly favored Democrats in recent statewide elections. Kiggans and Turpin each spent over $500,000 on television advertisements. Kiggans won, 50.4% to 49.5%. The Washington Post reported that "Her record didn't always fit neatly along a party line." She voted to expand nondiscrimination protections for LGBTQ people and for environmental protection measures. In 2022, Kiggans introduced a bill to prohibit transgender girls from playing girls' sports and voted for an audit of the 2020 election.
Sources: en.wikipedia.org
On 10 December 2009, Mgr Yves Le Saux, Bishop of Le Mans, France, opened the diocesan process for the beatification of Zita. Zita was in the habit of spending several months each year in the diocese of Le Mans at St. Cecilia's Abbey, Solesmes, where three of her sisters were nuns. The actor is the French Association pour la Béatification de l'Impératrice Zita. The postulator for the cause is Alexander Leonhardt. Vice postulator for Hungary is Catholic theologian Norbert Nagy. The judge of the tribunal is Bruno Bonnet. The promoter of justice is François Scrive. With the opening of her cause, the late Empress has been named Servant of God.
==== Carotenosis ==== Carotenoderma, also referred to as carotenemia, is a benign and reversible medical condition where an excess of dietary carotenoids results in orange discoloration of the outermost skin layer. It is associated with a high blood β-carotene value. This can occur after a month or two of consumption of β-carotene rich foods, such as carrots, carrot juice, tangerine juice, mangos, or in Africa, red palm oil. β-carotene dietary supplements can have the same effect. The discoloration extends to palms and soles of feet, but not to the white of the eye, which helps distinguish the condition from jaundice. Consumption of greater than 30 mg/day for a prolonged period has been confirmed as leading to carotenemia.
== Tissue Localization == Prepro-URP which is the precursor to the mature URP peptide is found in various tissues including specific parts of the brain such as frontal lobe and hypothalamus, and other peripheral tissues such as heart, kidneys, lungs, placenta, ovaries, and testes. In humans the amount of UII and URP gene expression are comparable except in the spinal cord where UII gene expression is much higher. In rats the UII gene expression is higher than the URP gene expression throughout the entire body. However, when the brains of the rats were tested, only the URP peptide was found making it the primary endogenous ligand in the brain. Unlike humans and rats, URP gene expression is found in mice spinal cords.
From the example above, if the descendant with genes A1 and B underwent another speciation event where gene A1 duplicated, the new species would have genes B, A1a, and A1b. In this example, genes A1a and A1b are symparalogs.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.